[Metastatic gastric cancer: does second-line chemotherapy make sense?].
Breithaupt
K
K
Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin.
Thuss-Patience
P C
PC
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D000077143:Docetaxel; D006801:Humans; D000077146:Irinotecan; D009367:Neoplasm Staging; D010166:Palliative Care; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D019233:Retreatment; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D000077146:Irinotecan; D002166:Camptothecin